Literature DB >> 31056438

Evaluation of treatment outcomes and factors associated with unsuccessful outcomes in multidrug resistant tuberculosis patients in Baluchistan province of Pakistan.

Imran Khan1, Nafees Ahmad2, Shereen Khan3, Shafi Muhammad4, Shabir Ahmad Khan5, Izaz Ahmad6, Asad Khan1, Muhammad Atif7.   

Abstract

BACKGROUND: Evaluating treatment outcomes of a cohort of patients is an effective way for analyzing the effectiveness of a program. Information regarding drug resistance pattern, detailed management, treatment outcomes and factors associated with unsuccessful outcomes in multidrug resistant (MDR-TB) patients is missing from Baluchistan province of Pakistan.
METHODS: This study was carried out at Programmatic Management of Drug Resistant TB unit at Fatimah Jinnah General and Chest Hospital Quetta. All eligible 186 MDR-TB patients enrolled at the study site from January 1, 2012 to April 30, 2016 were retrospectively followed until the treatment outcomes were reported. Data was abstracted through a standardized data collection form and analysed by SPSS 20. Multivariate binary logistic regression (MVBLR) analysis was used to evaluate factors associated with i) death and treatment failure and ii) lost to follow up. A p-value of <0.05 was considered statistically significant.
RESULTS: The study participants were resistant to a median of four drugs (range 2-8) with majority being resistant to any second-line anti-TB drug (SLD) (55.5%). Among SLD, resistance was highest for ofloxacin (52.2%). The study site had an overall treatment success rate of 71.6%. A total of 129 (69.4%) patients were cured, four (2.2%) completed treatment, 37 died (19.9%), 14 (7.5%) were lost to follow up and two (1.1%) were declared treatment failures. In MVBLR analysis, patients' age of >40 years (OR = 4.249, p-value = 0.001) had statistically significant positive and baseline body weight of >40 kg (OR = 0.256, p-value = 0.002) had statistically significant negative association with death and treatment failure. No factor had statistical significant association with lost to follow up.
CONCLUSION: Overall treatment success rate was promising but did not achieve the target success rate (>75%) set by World Health Organization. It can be further improved by paying special attention and providing enhanced management to the patients with risk factors for unsuccessful outcomes.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Baluchistan; Body weight; Death; MDR-TB; Ofloxacin

Mesh:

Substances:

Year:  2019        PMID: 31056438     DOI: 10.1016/j.jiph.2019.04.009

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN: 1876-0341            Impact factor:   3.718


  11 in total

1.  Development and Validation of a Nomogram for the Prediction of Unfavorable Treatment Outcome Among Multi-Drug Resistant Tuberculosis Patients in North West Ethiopia: An Application of Prediction Modelling.

Authors:  Denekew Tenaw Anley; Temesgen Yihunie Akalu; Mehari Woldemariam Merid; Tewodros Tsegaye
Journal:  Infect Drug Resist       Date:  2022-07-21       Impact factor: 4.177

2.  Treatment outcomes and associated factors among patients with multidrug-resistant tuberculosis in Ashanti Region, Ghana: a retrospective, cross-sectional study.

Authors:  Victoria Panford; Emmanuel Kumah; Collins Kokuro; Prince Owusu Adoma; Michael Afari Baidoo; Adam Fusheini; Samuel Egyakwa Ankomah; Samuel Kofi Agyei; Peter Agyei-Baffour
Journal:  BMJ Open       Date:  2022-07-05       Impact factor: 3.006

3.  Strengthening the response to drug-resistant TB in Pakistan: a practice theory-informed approach.

Authors:  S Abbas; M Kermode; S Kane
Journal:  Public Health Action       Date:  2020-12-21

4.  Treatment outcomes of extrapulmonary tuberculosis in Bahawalpur, Pakistan; a record review.

Authors:  Muhammad Atif; Razia Fatima; Nafees Ahmad; Zaheer-Ud-Din Babar
Journal:  J Pharm Policy Pract       Date:  2020-07-24

5.  Treatment Outcomes of Extensively Drug-Resistant Tuberculosis in Pakistan: A Countrywide Retrospective Record Review.

Authors:  Muhammad Abubakar; Nafees Ahmad; Abdul Ghafoor; Abdullah Latif; Izaz Ahmad; Muhammad Atif; Fahad Saleem; Shereen Khan; Amjad Khan; Amer Hayat Khan
Journal:  Front Pharmacol       Date:  2021-03-31       Impact factor: 5.810

6.  Incidence and predictors of mortality among persons receiving second-line tuberculosis treatment in sub-Saharan Africa: A meta-analysis of 43 cohort studies.

Authors:  Dumessa Edessa; Fuad Adem; Bisrat Hagos; Mekonnen Sisay
Journal:  PLoS One       Date:  2021-12-10       Impact factor: 3.240

7.  Prognostic accuracy of time to sputum culture conversion in predicting cure in extensively drug-resistant tuberculosis patients: a multicentre retrospective observational study.

Authors:  Muhammad Abubakar; Nafees Ahmad; Muhammad Atif; Izaz Ahmad; Abdul Wahid; Asad Khan; Fahad Saleem; Abdul Ghafoor
Journal:  BMC Infect Dis       Date:  2022-03-02       Impact factor: 3.090

8.  High rate of successful treatment outcomes among childhood rifampicin/multidrug-resistant tuberculosis in Pakistan: a multicentre retrospective observational analysis.

Authors:  Farah Naz; Nafees Ahmad; Abdul Wahid; Izaz Ahmad; Asad Khan; Muhammad Abubakar; Shabir Ahmed Khan; Amjad Khan; Abdullah Latif; Abdul Ghafoor
Journal:  BMC Infect Dis       Date:  2021-12-04       Impact factor: 3.090

9.  Drug resistance patterns, treatment outcomes and factors affecting unfavourable treatment outcomes among extensively drug resistant tuberculosis patients in Pakistan; a multicentre record review.

Authors:  Muhammad Atif; Saba Mukhtar; Sajjad Sarwar; Mehwish Naseem; Iram Malik; Azam Mushtaq
Journal:  Saudi Pharm J       Date:  2022-02-05       Impact factor: 4.562

10.  Incidence and factors associated with unfavourable treatment outcome among patients with rifampicin-resistant pulmonary tuberculosis in Yaoundé, Cameroon.

Authors:  Alain Kuaban; Adamou Dodo Balkissou; Marie Christine Essadi Ekongolo; Abdou Wouoliyou Nsounfon; Eric Walter Pefura-Yone; Christopher Kuaban
Journal:  Pan Afr Med J       Date:  2021-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.